公开(公告)号：US12156946B2

公开(公告)日：2024-12-03

申请号：US17016528

申请日：2020-09-10

Applicant: SOL-GEL TECHNOLOGIES LTD.

Inventor： Ofer Toledano ,  Haim Bar-Simantov ,  Nissim Bilman ,  Leora Shapiro ,  Raed Abu-Reziq ,  Hanan Sertchook

IPC: A61K9/50 ,  A01N25/26 ,  A01N53/00 ,  A61K8/11 ,  A61K8/25 ,  A61K8/38 ,  A61K8/67 ,  A61Q19/00 ,  B01J13/02 ,  B01J13/22 ,  C09C3/06

Abstract: The invention relates to a process for coating a solid, water-insoluble particulate matter, with a metal oxide comprising: (a) contacting the solid, water-insoluble particulate matter with an ionic additive and an aqueous medium to obtain a dispersion of said particulate matter having positive charges on its surface; (b) subjecting the particulate matter to a coating procedure comprising precipitating a metal oxide salt onto the surface of the particulate matter to form a metal oxide layer thereon to thereby obtain particulate matter coated by a metal oxide coating layer; (c) repeating step (b) at least 4 more times; and (d) aging said coating layer. The invention further relates to particles comprising a particulate matter coated by a metal oxide layer, to a use of the particles for topical administration, and to a method for preventing, reducing, or eliminating pests at a locus, using the particles.

公开(公告)号：US12053546B2

公开(公告)日：2024-08-06

申请号：US13537646

申请日：2012-06-29

Applicant: Ofer Toledano ,  Haim Bar-Simantov ,  Hanan Sertchook

Inventor： Ofer Toledano ,  Haim Bar-Simantov ,  Hanan Sertchook

IPC: A61K9/107 ,  A61K9/00 ,  A61K9/06 ,  A61K9/50 ,  A61K31/203 ,  A61K31/327 ,  A61K47/14

CPC classification number: A61K9/107 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/501 ,  A61K9/5084 ,  A61K31/203 ,  A61K31/327 ,  A61K47/14

Abstract: The present disclosure relates to compositions for topical application, where the compositions comprise microcapsules having a core that comprises benzoyl peroxide and a shell that comprises an inorganic polymer, microcapsules having a core that comprises a retinoid and a shell that comprises an inorganic polymer, and a stabilizing agent. The composition can be in a variety of forms, such as emulsion and gel.

公开(公告)号：US11986456B2

公开(公告)日：2024-05-21

申请号：US18076444

申请日：2022-12-07

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe Arkin ,  Karine Neimann ,  Ofer Toledano

IPC: A61K31/327 ,  A61K9/00 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/50 ,  A61P17/00 ,  A61P17/10

CPC classification number: A61K31/327 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/50 ,  A61P17/00 ,  A61P17/10

Abstract: A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.

公开(公告)号：US11877997B2

公开(公告)日：2024-01-23

申请号：US17156941

申请日：2021-01-25

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Ofra Levy-Hacham ,  Ori Nov ,  Vered Ram

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

CPC classification number: A61K31/327 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/50 ,  A61P17/00 ,  A61P17/10

Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.

公开(公告)号：US11865208B2

公开(公告)日：2024-01-09

申请号：US17023625

申请日：2020-09-17

Applicant: SOL-GEL TECHNOLOGIES LTD.

Inventor： Marina Shevachman ,  Amira Ze' Evi ,  Eilon Asculai ,  Batella Benyaminovich ,  Nir Avram ,  Chaim Aschkenasy

IPC: A61K9/00 ,  A61K9/16 ,  A61K31/565 ,  A61K31/4164 ,  A61K31/7056 ,  A61K31/4174 ,  A61K31/327 ,  A61K31/05 ,  A61K31/203 ,  A61K45/06 ,  A61K47/02 ,  A61K9/06 ,  A61K9/14 ,  A61K31/192 ,  A61K31/4436

CPC classification number: A61K9/0034 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/143 ,  A61K9/1611 ,  A61K31/05 ,  A61K31/192 ,  A61K31/203 ,  A61K31/327 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/4436 ,  A61K31/565 ,  A61K31/7056 ,  A61K45/06 ,  A61K47/02

Abstract: Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w/w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.

公开(公告)号：US20230390291A1

公开(公告)日：2023-12-07

申请号：US18453355

申请日：2023-08-22

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM ,  Ori NOV ,  Ofer TOLEDANO ,  Karine NEIMANN

IPC: A61K31/517 ,  A61P35/00 ,  A61K9/00

CPC classification number: A61K31/517 ,  A61P35/00 ,  A61K9/0014

Abstract: Provided herein compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichthyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

公开(公告)号：US11541026B2

公开(公告)日：2023-01-03

申请号：US17541847

申请日：2021-12-03

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe Arkin ,  Karine Neimann ,  Ofer Toledano

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

Abstract: A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.

公开(公告)号：US20220387349A1

公开(公告)日：2022-12-08

申请号：US17763231

申请日：2020-09-24

Applicant: Sol-Gel Technologies Ltd

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM

IPC: A61K31/05 ,  A61K9/00 ,  A61K47/20 ,  A61K47/10 ,  A61K47/22 ,  A61K47/14 ,  A61K9/10 ,  A61K47/02 ,  A61K47/32 ,  A61K47/12 ,  A61K47/18 ,  A61K9/107 ,  A61K47/44 ,  A61K47/06 ,  A61K9/06 ,  A61K47/26 ,  A61K47/24

Abstract: Provided herein is a topical composition comprising tapinarof and methods of treatment of cutaneous adverse effects caused by oncological therapy with the tapinarof composition. The tapinarof compositions of this invention are useful for the treatment, prevention or amelioration of cutaneous and/or mucosal adverse effect caused by oncological therapy selected from chemotherapy, immunotherapy, radiation therapy, targeted therapy, hormone therapy and stem cell transplant therapy.

公开(公告)号：US20220054467A1

公开(公告)日：2022-02-24

申请号：US17432927

申请日：2020-02-25

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN

IPC: A61K31/4436 ,  A61K31/05 ,  A61K9/00 ,  A61K9/06 ,  A61K47/44 ,  A61K47/10 ,  A61K47/20 ,  A61K47/18 ,  A61K47/32 ,  A61K47/12 ,  A61K47/02 ,  A61K45/06

Abstract: Provided herein is a topical combination composition comprising from about 0.25% w/w to about 2.0% w/w tapinarof, from about 0.025% w/w to about 0.1% w/w tazarotene and a carrier suitable for topical administration. Also provided is a topical combination composition comprising from about 0.25% w/w to about 2.0% w/w tapinarof, from about 0.025% w/w to about 0.1% w/w w tazarotene, from about 0.01% w/w to about 0.25% w/w at least one corticosteroid of potency class 1-4 and a carrier suitable for topical administration. The above compositions are useful for the treatment, prevention or alleviation of plaque psoriasis and exhibit synergistic and/or additive effects which allow reducing the amounts of the active agents in the compositions. The addition of tazarotene to tapinarof potentiates the tapinarof anti-psoriatic therapeutic effect.

公开(公告)号：US20220008356A1

公开(公告)日：2022-01-13

申请号：US17425956

申请日：2020-01-27

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN

IPC: A61K31/05 ,  A61K9/00 ,  A61K31/573 ,  A61K31/593 ,  A61K9/06 ,  A61K31/519

Abstract: Provided herein are topical combination compositions comprising a therapeutically effective dose of tapinarof and a therapeutically effective dose of at least one additional active agent, selected from at least one corticosteroid, calcipotriene, at least one JAK inhibitor and combinations thereof, and a carrier suitable for topical administration. The above compositions are useful for the treatment, prevention or alleviation of skin disorders selected from psoriasis and atopic dermatitis and exhibit synergistic or additive effects which allow reducing the doses of the active agents in the compositions.